ERBB2 and breast cancer: These observations are in line with published real-world studies showing that, even after trastuzumab approval, 10–30% of patients with early-stage HER2-positive breast cancer received chemotherapy alone without targeted therapy, particularly in earlier years or among elderly/comorbid patients [41, 42].